Synthesis, molecular modeling and evaluation of novel N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone derivatives as dual inhibitors for cholinesterases and Aβ aggregation.
To develop new drugs for treatment of Alzheimer's disease, a group of N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones was designed, synthesized and tested for their ability to inhibit acetylcholinesterase, butyrylcholinesterase and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42). The enzyme inhibition assay results indicated that compounds moderately inhibit both acetylcholinesterase and butyrylcholinesterase. β-Amyloid aggregation results showed that all compounds exhibited remarkable Aβ fibril aggregation inhibition activity with a nearly similar potential as the reference compound rifampicin, which makes them promising anti-Alzheimer drug candidates. Docking experiments were carried out with the aim to understand the interactions of the most active compounds with the active site of the cholinesterase enzymes.
T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 T13
CHEMICAL CHEMICAL CHEMICAL GENE-Y GENE-Y GENE-N GENE-Y GENE-Y GENE-Y GENE-Y GENE-Y GENE-Y GENE-Y
rifampicin N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone acetylcholinesterase butyrylcholinesterase amyloid beta peptides (1-40, 1-42 and 1-40_1-42) acetylcholinesterase butyrylcholinesterase β-Amyloid Aβ cholinesterase cholinesterases Aβ